Safety, Tolerability and Pharmacokinetics of BIIB118 (PF-05251749)

Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo

Single ascending doses of BIIB118 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo

Single dose (Maximum Tolerated Dose) of BIIB118 as extemporaneously prepared solution/suspension